An Open-label, Prospective, Randomized, Phase III, International Multicenter Clinical Study to Compare Radiotherapy Plus Nimotuzumab Versus Radiotherapy Alone in Platinum-Ineligible Patients With Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC)
Latest Information Update: 19 Jan 2026
At a glance
- Drugs Nimotuzumab (Primary)
- Indications Head and neck cancer
- Focus Therapeutic Use
Most Recent Events
- 19 Jan 2026 New trial record